Journal
ACTA DERMATO-VENEREOLOGICA
Volume 95, Issue 1, Pages 12-19Publisher
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-1825
Keywords
malassezia; seborrhoeic dermatitis; pityriasis versicolor; malassezia folliculitis; guidelines
Categories
Funding
- Astellas Pharma
- Gilead Sciences
- Merck Sharp and Dohme (MSD)
- Pfizer
- Schering Plough
- Galderma
- Medinor A/S
- Schering-Plough
- Leo Pharma
- Swedish Orphan
Ask authors/readers for more resources
Internationally approved guidelines for the diagnosis and management of Malassezia-related skin diseases are lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspices of the Danish Society of Dermatology undertook a data review and compiled guidelines for the diagnostic procedures and management of pityriasis versicolor, seborrhoeic dermatitis and Malassezia folliculitis. Main recommendations in most cases of pityriasis versicolor and seborrhoeic dermatitis include topical treatment which has been shown to be sufficient. As first choice, treatment should be based on topical antifungal medication. A short course of topical corticosteroid or topical calcineurin inhibitors has an anti-inflammatory effect in seborrhoeic dermatitis. Systemic antifungal therapy may be indicated for widespread lesions or lesions refractory to topical treatment. Maintenance therapy is often necessary to prevent relapses. In the treatment of Malassezia folliculitis systemic antifungal treatment is probably more effective than topical treatment but a combination may be favourable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available